NHMRC Clinical Trials Centre
Established in 1988, the NHMRC Clinical Trials Centre (CTC) now has a diverse group of 150 researchers. We have earned an outstanding reputation for contributing to major advances in clinical care via our high-quality collaborative clinical trials research.
Clinical trials research determines how existing drugs and treatments can be used most effectively and explores promising new therapies. Trials answer questions such as:
Is it better for patients with various cancers to have chemotherapy, radiotherapy, or both?
How should patients with heart disease be best treated to reduce the risk of heart attacks or strokes?
What are the benefits and risks of providing higher or lower levels of extra oxygen to very premature newborn babies?
The answers to these types of trials questions have led to important advances in patient care, which have resulted in better health outcomes for patients globally.
For example, thousands of lives are saved each year as a result of new cholesterol treatments, and patients are living longer, better-quality lives as a result of improved therapies for breast, lung, bowel and other cancers.
Towards the futureWe will continue our efforts to make clinical trials an integral part of health care. We also plan to maintain and build our global collaborative ties with other research networks, universities, government, and industry, to answer important clinical questions in new therapy areas.
Sub-collections in this collection
Published 2022Objectives: The highly transmissible COVID-19 Delta variant (DV) has contributed to a surge in cases and exacerbated the worldwide public health crisis. Several COVID-19 vaccines play a significant role in a high degree ...Article
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial Published 2022The CLARITY trial (Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease) is a two-arm, multi-centre, randomised controlled trial being run in India and Australia that investigates the ...Article
Care of older people and people requiring palliative care with COVID-19: guidance from the Australian National COVID-19 Clinical Evidence Taskforce Published 2022Introduction: Older people living with frailty and/or cognitive impairment who have coronavirus disease 2019 (COVID-19) experience higher rates of critical illness. There are also people who become critically ill with ...Article
Trimming the fat: is there a health economic case for use of new lipid lowering drugs in chronic kidney disease? A scoping review. Published 2021Background Individuals with chronic kidney disease (CKD) are at a very high risk for atherosclerotic cardiovascular disease (ASCVD). New lipid-lowering agents offer hope of improved outcomes where traditional agents have ...Article
Clinical care of children and adolescents with COVID-19: recommendations from the National COVID-19 Clinical Evidence Taskforce Published 2021INTRODUCTION: The epidemiology and clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are different in children and adolescents compared with adults. Although coronavirus ...Article